Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA known ✓ | P10253 | 1/20 | 0.47 |
| ▸ | PPARG known ✓ | P37231 | 1/20 | 0.45 |
| ▸ | IDO1 | P14902 | 4/20 | 0.55 |
| ▸ | HTT | P42858 | 4/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.50 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.50 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.50 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.50 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.50 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.50 |
| ▸ | POLB | P06746 | 1/20 | 0.50 |
| ▸ | MAPT | P10636 | 3/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.47 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.47 |
| ▸ | NPC1 | O15118 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | RAB9A | P51151 | 1/20 | 0.47 |
| ▸ | MEN1 | O00255 | 2/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8223381 | 0.98 | IDO1 (0.54) | IDO1HTTALDH1A1CYP1A2CYP3A4 | |
| SCHEMBL30480073 | 0.98 | IDO1 (0.54) | IDO1HTTALDH1A1CYP1A2CYP3A4 | |
| Hydrochloric Acid SCHEMBL31429947 | 0.83 | ALDH1A1 (0.44) | IDO1HTTALDH1A1CYP3A4POLB | |
| SCHEMBL8221733 | 0.81 | ALDH1A1 (0.46) | IDO1HTTALDH1A1CYP1A2CYP3A4 | |
| SCHEMBL14656662 | 0.80 | HTT (0.65) | IDO1HTTALDH1A1CYP1A2CYP3A4 | |
| Hydrochloric Acid SCHEMBL20529751 | 0.80 | MAPK1 (0.52) | IDO1HTTALDH1A1CYP1A2CYP3A4 | |
| Hydrochloric Acid SCHEMBL3591332 | 0.79 | HTT (0.59) | IDO1HTTCYP1A2CYP3A4CYP2C9 | |
| SCHEMBL15076829 | 0.78 | CXCR3 (0.43) | ALDH1A1CYP1A2CYP2C9CYP2C19POLB | |
| SCHEMBL31351537 | 0.78 | PYCR1 (0.42) | IDO1HTTALDH1A1CYP1A2CYP3A4 | |
| SCHEMBL11621445 | 0.78 | P2RX7 (0.43) | ALDH1A1CYP1A2CYP3A4CYP2C9CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3843714-B1 | CD73 INHIBITORS | ARCUS BIOSCIENCES INC (US) | 2025-11-12 | — | — | EP | disclosed |
| CN-120040348-A | Preparation method for efficiently synthesizing CB1 antagonist pyrazole derivative | 中国药科大学 | 2025-05-27 | — | — | CN | disclosed |
| CN-119798177-A | In the sulfenamide Process for the preparation of intermediates | 宁夏格瑞精细化工有限公司 | 2025-04-11 | — | — | CN | disclosed |
| CN-115850123-B | Preparation method of 2, 4-dichloroaniline/hydrazine | 山东潍坊润丰化工股份有限公司 | 2024-04-19 | — | — | CN | disclosed |
| US-11931343-B2 | CD73 inhibitors | ARCUS BIOSCIENCES, INC. (US) | 2024-03-19 | — | — | US | disclosed |
| US-20210253562-A1 | ACYLSUFONAMIDE COMPOUNDS USEFUL AS EP3 RECEPTOR ANTAGONISTS | JANSSEN PHARMACEUTICA NV (BE) | 2021-08-19 | — | — | US | disclosed |
| WO-2020008317-A1 | ACYLSUFONAMIDE COMPOUNDS USEFUL AS EP3 RECEPTOR ANTAGONISTS | JANSSEN PHARMACEUTICA NV (BE) | 2020-01-09 | — | — | WO | disclosed |
| US-10246462-B2 | Chemokine receptor modulators and uses thereof | FLX BIO, INC. (US) | 2019-04-02 | — | — | US | disclosed |
| WO-2018187509-A1 | HETEROCYCLIC COMPOUNDS AS CHEMOKINE RECEPTOR MODULATORS | FLX BIO, INC. (US) | 2018-10-11 | — | — | WO | disclosed |
| US-20180072743-A1 | CHEMOKINE RECEPTOR MODULATORS AND USES THEREOF | RAPT THERAPEUTICS, INC. | 2018-03-15 | — | — | US | disclosed |
| WO-2018049271-A1 | CHEMOKINE RECEPTOR MODULATORS AND USES THEREOF | FLX BIO, INC. (US) | 2018-03-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10246462-B2 | Chemokine receptor modulators and uses thereof | ACKR3, CCR5, CXCR3 | GAA 4531/4885PPARG 645/4885IDO1 1441/4885 |
| US-20180072743-A1 | CHEMOKINE RECEPTOR MODULATORS AND USES THEREOF | ACKR3, CCR5, CXCR3 | GAA 4531/4885PPARG 645/4885IDO1 1441/4885 |
| US-20210253562-A1 | ACYLSUFONAMIDE COMPOUNDS USEFUL AS EP3 RECEPTOR ANTAGONISTS | PTGER3, FFAR3, PTGES3 | GAA 3078/4885PPARG 144/4885IDO1 4112/4885 |
| US-11931343-B2 | CD73 inhibitors | ENTPD5, ENTPD1, NT5E | GAA 545/4885PPARG 3017/4885IDO1 132/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.